Target
VEGFR 1-3
9 abstracts
Abstract
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.Org: Jiangsu Cancer Hospital, Peking University First Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Nanchang University Branch Donghu, The People's Hospital of Guangxi Zhuang Autonomous Region,
Abstract
A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.Org: UPMC Hillman Cancer Center, Pittsburgh, PA, UT Health Science Center at San Antonio, Mays Cancer Center, San Antonio, TX,
Abstract
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.Org: 3rd Affiliated Hospital of ZhengZhou University,
Abstract
Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).Org: Department of Respiratory Medicine,Taizhou Hosipital of Zhejiang Province, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, The Southwest Hospital of AMU,
Abstract
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).Org: Medical Oncology Group, Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China, Beijing Cancer Hospital, Beijing, China,
Abstract
A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.Org: Fudan University Shanghai Cancer Center, The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Jilin Cancer Hospital, HUTCHMED Limited,
Abstract
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).Org: Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China, Medical Affairs Department, 3D Medicines, Shanghai, China,